Methods to recruit and retain a cohort of young-adult injection drug users for the Third Collaborative Injection Drug Users Study/Drug Users Intervention Trial (CIDUS III/DUIT)

Drug and Alcohol Dependence

Volumn 91, Issue SUPPL. 1, 2007, Pages

  Garfein, Richard S ^a,f   Swartzendruber, Andrea ^a   Ouellet, Lawrence J ^b   Kapadia, Farzana ^c   Hudson, Sharon M ^d   Thiede, Hanne ^e   Strathdee, Steffanie A ^f   Williams, Ian T ^g   Bailey, Susan L ^b   Hagan, Holly ^h   Golub, Elizabeth T ⁱ   Kerndt, Peter ^d   Hanson, Debra L ^a   Latka, Mary H ^c  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c NEW YORK ACADEMY OF MEDICINE   (United States)

^d Health Research Association   (United States)

^e Public Health Seattle and King County   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

ⁱ JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Behavioral intervention; Cohort; HCV prevalence; HIV prevalence; Injection drug use; Randomized controlled trial

Indexed keywords

HEPATITIS C ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ARTICLE; COHORT ANALYSIS; DEMOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION RISK; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SEROPREVALENCE; SEXUAL BEHAVIOR; TECHNIQUE; UNITED STATES; VIRUS INFECTION;

ADOLESCENT; ADULT; COHORT STUDIES; COMPENSATION AND REDRESS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HIV INFECTIONS; HUMANS; INFORMED CONSENT; MALE; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; RISK-TAKING; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; UNSAFE SEX;

HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS;

EID: 34548254603     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2007.05.007     Document Type: Article

References (52)

1. Bandura A. Social Foundations of Thought & Action (1986), Prentice-Hall, Englewood Cliffs, NJ
2. Bluthenthal R.N., Kral A.H., Gee L., Erringer E.A., and Edlin B.R. The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS 14 (2000) 605-611
3. Booth R.E., Kwiatkowski C.F., and Stephens R.C. Effectiveness of HIV/AIDS interventions on drug use and needle risk behaviors for out-of-treatment injection drug users. J. Psychoactive Drugs 30 (1998) 269-278
4. Browne R., Asboe D., Gilleece Y., Atkins M., Mandalia S., Gazzard B., and Nelson M. Increased numbers of acute hepatitis C infections in HIV positive homosexual men; is sexual transmission feeding the increase?. Sex. Transm. Infect. 80 (2004) 326-327
5. Centers for Disease Control and Prevention, 1998. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm. Rep. 47, 1-39.
6. Centers for Disease Control and Prevention, 1999. HIV/AIDS Prevention Research Synthesis Project. Compendium of HIV Prevention Interventions with Evidence of Effectiveness. Centers for Disease Control and Prevention, Atlanta, GA, pp. 1-6.
7. Centers for Disease Control and Prevention, 2003a. 2003-2008 HIV Prevention Community Planning Guide. Available at http://www.cdc.gov/hiv/pubs/hiv-cp.htm (accessed December 14, 2006).
8. Centers for Disease Control and Prevention, 2003b. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR Recomm. Rep. 52, 5.
9. Centers for Disease Control Prevention. HIV/AIDS Surveillance Report, 2003 vol. 15 (2004), US Department of Health and Human Services, Center for Disease Control and Prevention, Atlanta
10. Chaisson R.E., Moss A.R., Onishi R., Osmond D., and Carlson J.R. Human immunodeficiency virus infection in heterosexual intravenous drug users in San Francisco. Am. J. Public Health 7 (1987) 169-172
11. Deren S., Stephens R., Davis W.R., Feucht T.E., and Tortu S. The impact of providing incentives for attendance at AIDS prevention sessions. Public Health Rep. 109 (1994) 548-554
12. Des Jarlais D.C., Paone D., Milliken J., Turner C.F., Miller H., Gribble J., Shi Q., Hagan H., and Friedman S.R. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasi-randomised trial. Lancet 353 (1999) 1657-1661
13. Dolezal C., Meyer-Bahlburg H.F., Liu X., Ehrhardt A.A., Exner T.M., Rabkin J.G., Gorman J.M., Marder K., and Stern Y. Longitudinal changes in sexual risk behavior among HIV+ and HIV- male injecting drug users. Am. J. Drug Alcohol Abuse 25 (1999) 281-303
14. Fuller C.M., Vlahov D., Arria A.M., Ompad D.C., Garfein R., and Strathdee S.A. Factors associated with adolescent initiation of injection drug use. Public Health Rep. 116 Suppl. 1 (2001) 136-145
15. Fisher J.D., and Fisher W. Changing AIDS-risk behavior. Psychol. Bull. 111 (1992) 455-474
16. Garfein R.S., Vlahov D., Galai N., Doherty M.C., and Nelson K.E. Viral infections among short-term injection drug users: the prevalence of hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotrophic viruses. Am. J. Public Health 86 (1996) 655-661
17. Garfein R.S., Vlahov D., Doherty M.C., Thomas D., Monterroso E., and Nelson K.E. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J. Acquired Immune Defic. Syndr. Hum. Retrovirol. 18 (1998) S11-S19
18. Garfein R.S., Golub E.T., Greenberg A., Hagan H., Hanson D.L., Hudson S., Kapadia F., Latka M.H., Ouellet L., Purcell D.W., Strathdee S.A., Thiede H., and for the DUIT Study Team. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS 21 14 (2007) 1923-1932
19. Greenberg J., Lifshay J., Van Devanter N., Gonzales V., and Celentano D. Preventing HIV infection: the effects of community linkages, time, and money on recruiting and retaining women in intervention groups. J Women's Health 7 (1998) 587-596
20. Hagan H., Thiede H., Weiss N.S., Hopkins S.G., Duchin J.S., and Alexander E.R. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am. J. Public Health 91 (2001) 42-46
21. Hahn J.A., Page-Shafer K., Lum P.J., Bourois P., Stein E., Evens J.L., Busch M.P., Tobler L.H., Phelps B., and Moss A.R. Hepatitis C virus seroconversion among young injection drug users: relationship and risk. J. Infect. Dis. 186 (2002) 1558-1564
22. Heckathorn D.D. Respondent-driven sampling: a new approach to the study of hidden populations. Social Problems 44 (1997) 174-199
23. Heckathorn D.D., Semaan S., Broadhead R.S., and Hughes J.J. Extension of respondent-driven sampling: a new approach to the study of injection drug users aged 18-25. AIDS Behav. 6 (2002) 55-67
24. Hser Y., Anglin M.D., and McGlothlin W. Sex differences in addict careers. 1. Initiation of use. Am. J. Drug Alcohol Abuse 13 (1987) 33-57
25. Hutchinson A.B., Branson B.M., Kim A., and Farnham P.G. A meta-analysis of the effectiveness of alternative HIV counseling and testing methods to increase knowledge of HIV status. AIDS 20 (2006) 1597-1604
26. Institute of Medicine, 2001. Report Brief. No Time to Lose: Getting the Most From HIV Prevention. National Academies Press, Washington, DC. Available at: http://www.iom.edu/CMS/3793/5549.aspx (accessed December 14, 2006).
27. Juni P., Altman D.G., and Egger M. Assessing the quality of randomised controlled trials. In: Egger M., Smith G.D., and Altman D.G. (Eds). Systematic Reviews in Health Care: Meta-analysis in Context (2001), BMJ Publishing Group, London, England 87-108
28. Kamb, M.L., Fishbein, M., Douglas, J.M. Jr, Rhodes, F., Rogers, J., Bolan, G., Zenilman, J., Hoxworth, T., Malotte, C.K., Iatesta, M., Kent, C., Lentz, A., Graziano, S., Byers, R.H., Peterman, T.A., 1998a. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: a randomized controlled trial. Project RESPECT Study Group. JAMA 280, 1161-1167.
29. Kamb, M.L., Rhodes, F., Hoxworth, T., Rogers, J., Lentz, A., Kent, C., MacGowen, R., Peterman, T.A., for the Project RESPECT, 1998b. What about money? Effect of small monetary incentives on enrollment, retention, and motivation to change behaviour in an HIV/STD prevention counselling intervention. Sex. Transm. Infect. 74, 253-255.
30. Kellerman S., Begley E., Boyett B., Clark H., and Schulden J. Changes in HIV and AIDS in the United States: entering the third decade. Curr. HIV/AIDS Rep. 1 (2004) 153-158
31. Kral A.H., Bluthenthal R.N., Lorvick J., Gee L., Bacchetti P., and Edlin B.R. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 357 (2001) 1397-1401
32. Lyles, C.M., Crepaz, N., Herbst, J.H., Kay, L.S., HIV/AIDS Prevention Research Synthesis Team, 2006. Evidence-based HIV behavioral prevention from the perspective of the CDC's HIV/AIDS Prevention Research Synthesis Team. AIDS Educ. Prev. 18 (4 Suppl. A), 21-31.
33. Marmor M., Des Jarlais D.C., Cohen H., Friedman S.R., Beatrice S.T., Dubin N., el-Sadr W., Mildvan D., Yancovitz S., and Mathur U. Risk factors for infection with human immunodeficiency virus among intravenous drug abusers in New York City. AIDS 1 (1987) 39-44
34. Marmor M., Titus S., Wolfe H., Krasinski K., Maslansky R., Simberkoff M., Beatrice S., Nichols S., and Des Jarlais D.C. Preparations for AIDS vaccine trials. Retention, behavior change, and HIV-seroconversion among injecting drug users (IDUs) and sexual partners of IDUs. AIDS Res. Hum. Retroviruses 10 (1994) S207-S213
35. Metzger D.S., Koblin B., Turner C., Navaline H., Valenti F., Holte S., Gross M., Sheon A., Miller H., Cooley P., and Seage III G.R. Randomized controlled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. HIVNET Vaccine Preparedness Study Protocol Team. Am. J. Epidemiol. 152 (2000) 99-106
36. Ompad D.C., Ikeda R.M., Shah N., Fuller C.M., Bailey S., Morse E., Kerndt P., Maslow C., Wu Y., Vlahov D., Garfein R., and Strathdee S.A. Childhood sexual abuse and age at initiation of injection drug use. Am. J. Public Health 95 (2005) 703-709
37. Purcell D.W., et al. Development, description, and acceptability of a small-group, behavioral intervention to prevent HIV and hepatitis C virus Infections among young adult injection drug users. Drug and Alcohol Dependence 91 Suppl. 1 (2007) S73-S80
38. Ruan Y., Qin G., Liu S., Qian H., Zhang L., Zhou F., He Y., Chen K., Yin L., Chen X., Hao Q., Xing H., Song Y., Wang Y., Hong K., Chen J., and Shao Y. HIV incidence and factors contributed to retention in a 12-month follow-up study of injection drug users in Sichuan Province, China. J. Acquired Immune Defic. Syndr. 39 (2005) 459-463
39. Schoenbaum E.E., Hartel D., Selwyn P.A., Klein R.S., Davenny K., Rogers M., Feiner C., and Friedland G. Risk factors for human immunodeficiency virus infection in intravenous drug users. N. Engl. J. Med. 321 (1989) 874-879
40. Strathdee S.A., Galai N., Safaiean M., Celentano D.D., Vlahov D., Johnson L., and Nelson K.E. Sex differences in risk factors for HIV seroconversion among injection drug users: a 10-year perspective. Arch. Intern. Med. 161 (2001) 1281-1288
41. Strathdee S.A., and Sherman S.G. The role of sexual transmission of HIV infection among injection and non-injection drug users. J. Urban Health 80 (2003) iii7-iii14
42. Sullivan P.S., Lansky A., and Drake A. Failure to return for HIV test results among persons at high risk for HIV infection. Results from a multistate interview project. J. Acquired Immune Defic. Syndr. 25 (2004) 511-518
43. Sullivan L.E., Metzger D.S., Fudala P.J., and Fiellin D.A. Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users. Addiction 100 (2005) 150-158
44. Thomas D.L., Shih J.W., Alter H.J., Vlahov D., Cohn S., Hoover D.R., Cheung L., and Nelson K.E. Effects of human immunodeficiency virus on hepatitis C infection among injecting drug users. J. Infect. Dis. 174 (1996) 690-695
45. Thorpe L.E., Ouellet L.J., Levy J.R., Williams I.T., and Monterroso E.R. Hepatitis C virus infection: prevalence, risk factors, and prevention among young injection drug users in Chicago, 1997-1999. J. Infect. Dis. 1822 (2000) 1588-1594
46. Thorpe L.E., Ouellet L.J., Hershow R., Bailey S.L., Williams I.T., Williamson J., Monterroso E.R., and Garfein R.S. Risk for hepatitis C virus infection among young adult injection drug users who share injection equipment, Chicago 1997-1999. Am. J. Epidemiol. 155 (2002) 645-653
47. Turner C.F., Ku L., Rogers S.M., Lindberg L.D., Pleck J.H., and Sonenstein F.L. Adolescent sexual behavior, drug use, and violence: increased reporting with computer survey technology. Science 280 (1998) 867-873
48. Valdiserri R.O., Moore M., Gerber A.R., Campbell C.H., Dillon B.A., and West G.R. A study of clients returning for counseling after HIV testing: implications for improving rates of return. Public Health Rep. 108 (1993) 12-18
49. Vlahov D., Munoz A., Anthony J.C., Cohn S., Celentano D.D., and Nelson K.E. Association of drug injection patterns with antibody to human immunodeficiency virus type 1 among intravenous drug users in Baltimore, Maryland. Am. J. Epidemiol. 132 (1990) 847-856
50. Vlahov D., Anthony J.C., Munoz A., Margolick J., Nelson K.E., Celentano D.D., Solomon L., and Polk E.F. The ALIVE Study: a longitudinal study of HIV-1 infection in intravenous drug users: description of methods. J. Drug Issues 21 (1991) 759-776
51. Wiebel W.W., Jimenez A., Johnson W., Ouellet L., Jovanovic B., Lampinen T., Murray J., and O'Brien M.U. Risk behavior and HIV seroincidence among out-of-treatment injection drug users: a four-year prospective study. J. Acquired Immune Defic. Syndr. 12 (1996) 282-289
52. Wejstal R. Sexual transmission of hepatitis C virus. J. Hepatol. 31 (1999) 92-95